The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Topics


  • Mechanism(s) of action of molecularly targeted agents including synthetic lethality and combination therapies
  • Molecular approaches to target circulating tumor cells, cancer stem cells, miRNA expression, signaling molecules, epigenetic regulators, and oncogenic noncoding RNAs
  • Mechanisms of action of molecular and genetic-based targeted therapies in a translational setting using preclinical models and clinical samples
  • Identification, validation, and functional evaluation of novel molecular targets (including companion biomarkers) for cancer treatment and synergistic drug combination as well as system biology approaches
  • Novel targets of tumor microenvironment, metabolomic processes and angiogenesis for cancer drug discovery

Shared Interests and Overlaps

Overlap with Mechanisms of Cancer Therapeutics-1 (MCT1) occurs for applications focus on the Mechanism(s) of action of anti-neoplastic agents and or combinations of agents at the molecular, cellular, or target tissue level may be assigned to either MCT1 or MCT2. For applications that investigate the resistance mechanism(s) of anti-neoplastic agents and strategies may be assigned to MCT1. Applications that focus on Mechanism(s) of action for molecularly targeted agents including synthetic lethality and combination therapies may be assigned to MCT2.

There are shared interests with Mechanisms of Cancer Therapeutics-1 (MCT1)for applications that utilize preclinical models and clinical samples for the studies. For applications that focus on cancer drug discovery in the translational setting using preclinical models and clinical samples may be assigned to MCT1. Applications that focus on elucidation of the mechanisms of action of molecular- and genetic-based targeted cancer therapies setting using preclinical models and clinical samples may be assigned to MCT2.

There are shared interests with Developmental Therapeutics (DT) in the therapeutic evaluation of the anti-cancer drug effect. Applications that focus on the development of anti-angiogenic therapeutic strategies and rational combinations of cytotoxic drugs with novel agents may be assigned to DT. Applications that focus on identification, validation, and functional evaluation of novel molecular targets (including companion biomarkers) for cancer treatment and synergistic drug combination may be assigned to MCT2.

There are shared interests with Drug Discovery and Molecular Pharmacology (DMP) in the identification of molecular targets of agents. Applications that focus on new drug development and production (chemical synthesis) may be assigned to DMP. Applications that focus on evaluation of the inhibitors targeting circulating tumor cells, cancer stem cells, miRNA expression, signaling molecules, epigenetic regulators, and oncogenic noncoding RNAs may be assigned to MCT2.

There are shared interests with Tumor Microenvironment Study Section (TME) in the investigation of the effects of tumor microenvironment. Applications that focus on the basic mechanisms of interactions between tumor and host system may be assigned to TME. Applications that focus on targeting the tumor microenvironment may be assigned to MCT2.

There are shared interests with Tumor Cell Biology Study Section (TCB) in the study of the signaling pathways. Applications that involve signal transduction mechanisms in neoplastic cells may be assigned to TCB. Applications that focus on the mechanisms of action of molecular and genetic-based targeted therapies in a translational setting using preclinical models and clinical samples may be assigned to MCT2.

There are shared interests with Tumor Cell Biology Study Section (TCB) in the investigation of cancer cell metabolism. Applications that focus on the mechanisms that modulate cancer cell metabolism and tumor progression may be assigned to TCB. Applications that focus on targeting of tumor metabolomic processes may be assigned to MCT2.

There are shared interests with Tumor Progression and Metastasis Study Section (TPM) in the investigation of cancer stem cells. Applications that focus on the role of stem cells in tumor metastasis and angiogenesis may be assigned to TPM. Applications that involve inhibitors targeting cancer stem cells and targeting angiogenesis for cancer drug discovery may be assigned to MCT2.